CG
BDTX icon

Cutler Group’s Black Diamond Therapeutics BDTX Stock Holding History

Cutler Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,100
Closed -$6K – 3778
2023
Q2 		$6K Buy
+11,100
New +$22.7K ﹤0.01% 2502

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Cutler Group's BDTX Position: Q1 2024 in Review

Cutler Group increased its Black Diamond Therapeutics (BDTX) stake by 17% in Q1 2024, buying an estimated $403 and bringing the position to 700 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1684.

Cutler Group first reported a position in BDTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $9K in Q2 2022. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

  • Cutler Group held 700 shares of Black Diamond Therapeutics worth $3K as of Q1 2024.
  • Cutler Group bought 100 Black Diamond Therapeutics shares in Q1 2024, an estimated $403.
  • Black Diamond Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1684 holding.
  • Cutler Group first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Cutler Group's Black Diamond Therapeutics position peaked at $9K in Q2 2022.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.